Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m.

PRNewsWire • Feb 3, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026.

PRNewsWire • Feb 3, 2026

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.

PRNewsWire • Jan 20, 2026

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.

PRNewsWire • Jan 8, 2026

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewsWire • Jan 6, 2026

Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?

Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Jan 6, 2026

Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates

VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.

Zacks Investment Research • Dec 19, 2025

Viatris Provides Pipeline Update on Four Regulatory Milestones

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for Low Dose Estrogen Weekly Patch for Contraception U.S. FDA Clears Investigational New Drug Application for MR-146 in Neurotrophic Keratopathy Japan Pharmaceuticals and Medical Devices Agency Accepts Japanese New Drug Application Filing for Pitolisant in Obstructive Sleep Apnea Syndrome PITTSBURGH , Dec. 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: Octreotide Acetate for Injectable Suspension: The U.S. Food and Drug Administration (FDA) has approved the Company's octreotide acetate for injectable suspension, a generic version of Sandostatin® LAR Depot. The therapy is indicated for treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide secreting tumors.

PRNewsWire • Dec 18, 2025

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026.

PRNewsWire • Dec 17, 2025